Advances in targeted therapy for esophageal cancer

Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy and chemotherapy are the primary clinical treatments for esophageal cancer. However, outcomes are still unsatisfactory due to the limited efficacy and severe adverse effects of conventional treatments. As a new type of approach, targeted therapies have been confirmed to play an important role in the treatment of esophageal cancer; these include cetuximab and bevacizumab, which target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), respectively. In addition, other drugs targeting surface…

• NN
  National Natural Science Foundation of China

  Awards: 2017YFA0505100, 81672953, 81973339, 81773085, 31961160727, 81803551, 31570828, 31770888
• NK
  National Key Research and Development Program of China

  Award: 2017YFA0505100
• FR
  Fundamental Research Funds for the Central Universities

  Award: 21620429